On 7 June 2021, Nanexa AB (Plc.) decided to conduct a preferential rights issue of shares worth approximately SEK 126.7 million. The preferential rights issue is fully covered by subscription commitments and guarantee commitments. In addition, the Board of Directors may decide to implement an over-allotment issue in the form of a directed issue of a maximum of approx. SEK 23.5 million, provided that the preferential rights issue is fully subscribed.
Nanexa AB is a nanotechnological drug delivery company focused on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential in a number of substance types and indication areas. Within the context of PharmaShell®, Nanexa develops its own projects and has cooperation agreements with several pharmaceutical companies. Nanexa’s shares are listed on the Nasdaq First North Growth Market.
Lindahl has advised Nanexa with a team consisting of Gunnar Mattsson, Michael Edquist, Erika Svensson and Erik Vikström, among others. ABG Sundal Collier has acted as the sole global coordinator and bookrunner.
